Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-c therapy

Hematopathology and Molecular Hematology

Volumn 10, Issue 4, 1996, Pages 213-222

  Straetmans, Nicole ^a   David, D F ^a,b   Nevell, D F ^a   Arthur, C ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN; CELL ADHESION MOLECULE; CELL ANTIGEN; COLLAGEN; CYTARABINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HLA DR ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; RETICULIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEGAKARYOCYTE; MYELOFIBROSIS; PRIORITY JOURNAL; STROMA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIGENS; ANTIGENS, CD; ANTIGENS, CD31; ANTIGENS, CD34; BONE MARROW EXAMINATION; CYTARABINE; E-SELECTIN; ENDOTHELIUM; FEMALE; FIBROSIS; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN BETA3; INTERFERON-ALPHA; LECTINS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MYELOFIBROSIS; PLANT LECTINS; PLATELET MEMBRANE GLYCOPROTEINS; RETICULIN; RETROSPECTIVE STUDIES; STAINING AND LABELING; STROMAL CELLS; VON WILLEBRAND FACTOR;

EID: 0030499473     PISSN: 10828893     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Talpaz M. Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314:1065, 1986.
2. Allan NC, Richards SM, Shepherd PCA on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia: UK Medical Research Council randomized, multicentre trial of interferon-αn1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995.
3. The Italian Cooperative Study Group on chronic myeloid leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994.
4. Talpaz M, Spitzer G, Hittelman W, Kantarjian H, Gutterman J: Changes in granulocyte-monocyte colonyforming cells among leukocyte-interferon treated chronic myelogenous leukemia patients. Exp Hematol 14:668, 1986.
5. Galvani DW, Cawley JC: Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br J Hematol 73:475, 1989.
6. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF: Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukemia. Nature 328:342, 1987.
7. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman JM, Gordon M: Interferon-a overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78:499, 1991.
8. Bhatia R, McGlave PB, Verfaillie CM: Interferon - a treatment of normal bone marrow stroma in enhanced adhesion of chronic myelogenous leukemia hematopoietic progenitors via mechanisms involving MIP-Ia and TGF-13. Exp Hematol 22:797, 1994.
9. Arthur CK, Ma DDF: Combined interferon Alfa-2a and Cytosine Arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol 89(suppl 1):15, 1993.
10. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F: Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 63:789, 1984.
11. Erber WN, McLachlan J: Use of APAAP technique on paraffin wax embedded bone marrow trephines. J Clin Pathol 42:1201, 1989.
12. Bradbury P, Gordon KC: Connective tissues and stains. In: Theory and Practice of Histological Techniques. Edited by JD Bancroft, A Stevens. Churchill Livingstone, New York, p 122, 1982.
13. Bauermeister DE: Quantitation of bone marrow reticulin - a normal range. Am J Clin Pathol 56:24, 1971.
14. Clough V, Geary CG, Hashmi K, Davson J, Knowlson T: Myelofibrosis in chronic granulocytic leukaemia. Br J Haematol 42:515, 1979.
15. Thiele J, Kyasnicka HM, Niederle N, Zirbes TK, Schmidt M, Dammasch J, Meuter BR, Leder LD, Kloke O, Diehl V, Fischer R: The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML - a comparative morphometric study on sequential trephine biopsies. Ann J Hematol 70:121, 1994.
16. Auerbach R: Vascular endothelial cell differentiation: organ specificity and selective affinities as the basis for developing anticancer strategies. Intl J Radiation Biol 60:1, 1991.
17. Holthofer H, Virtanen I, Kariniemi AL, Hormia M, Linder E, Miettinen A: Ulex Europaeus I lectin as a marker for vascular endothelium in human tissues. Lab Invest 47:60, 1982.
18. Paul LC, van Es LA, Balwin WM: Antigens in human renal allografts. Clin Immunol Immunopathol 19:206, 1981.
19. Dilly SA, Jagger CJ: Bone marrow stromal changes in hematological malignancies. J Clin Pathol 43:942, 1990.
20. Civin CI: Human monomyeloid cell membrane antigens. Exp Hematol 18:461, 1990.
21. Simmons PJ, Torok-Storb B: CD34 expression by stromal precursors in normal human adult bone marrow. Blood 78:2848, 1991.
22. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monoghan P, Delia D, Sutherland DR, Baker MA, Greaves MF: Expression of the CD34 gene in vascular endothelial cells. Blood 75:2417, 1990.
23. Baumhueter S, Dybdal L, Kyle C, Lasky LA: Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin. Blood 84:2554, 1994.
24. + myeloid progenitors: role of bone marrow stromal, fibroblast, and cytomatrix components. Exp Hematol 19:63, 1991.
25. Straetmans N, Ma DDF: Cell adhesion molecules and their role in hemopoiesis and in hematological diseases. Aust NZ J Med 23:504, 1993.
26. Bhatia R, McCarthy JB, Verfaillie CM: Interferon-a restores normal β1 medicated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myeloid leukemia. Blood 87:3883, 1996.
27. Albeda SM, Muller WA, Buck CA, Newman PJ: Molecular and cellular properties of PECAM-I (EndoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol 117:1059, 1991.
28. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY: JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752, 1990.
29. Simmons PJ, Niutta S, Ashman LK, Bemdt MC, Juttner CA: Primitive human bone marrow progenitors express L-selectin and PECAM-1 (CD31). Exp Hematol 20:468, 1992.
30. Kieffer N, Fitzgerald LA, Wolf D, Cheresh DA, Phillips DR: Adhesive properties of the β3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol 113:451, 1991.
31. Gordon MY, Clarke D, Atkinson J, Greaves MF: Hematopoietic progenitor cell binding to the stromal microenvironment in vitro. Exp Hematol 18:837, 1990.